Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Thoracic Oncology

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e3181653cf4PMID 18317067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2007

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

  2007cited by this paper
• EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells?

  2007cited by this paper
• B3-07: A phase II study of Cetuximab (C225) in combination with chemoradiation

  2007cited by this paper
• Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

  2007cited by this paper
• Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer

  2007cited by this paper
• EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.

  2007cited by this paper
• Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023

  2007cited by this paper
• Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.

  2006cited by this paper
• Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial.

  2006cited by this paper
• Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.

  2006cited by this paper
• Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105.

  2006cited by this paper
• High-dose 3D chemoradiotherapy trials in stage III non-small cell lung cancer (NSCLC) at the University of North Carolina: Long-term follow up and late complications.

  2006cited by this paper
• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

  2006cited by this paper
• Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer

  2005cited by this paper
• Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

  2005cited by this paper
• Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• EGFR mutation and response of lung cancer to gefitinib.

  2005cited by this paper
• Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

  2005cited by this paper
• Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

  2004cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

  2004cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer.

  2004cited by this paper
• Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.

  2004cited by this paper
• P-585 Long-term results of aggressive combined modality therapy employing induction and concurrent carboplatin/paclitaxel with dose-escalated thoracic conformal radiation therapy

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Epidermal growth factor receptor: mechanisms of activation and signalling.

  2003cited by this paper
• Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

  2002cited by this paper
• Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

  2002cited by this paper
• Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.

  2001cited by this paper
• Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

  2001cited by this paper
• Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma

  2001cited by this paper
• New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classification

  1992cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Cancer statistics

  1989cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper

• Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review

  2023influential citation
• Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

  2023cites this paper
• Study on drug screening multicellular model for colorectal cancer constructed by three-dimensional bioprinting technology

  2023cites this paper
• Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers

  2022cites this paper
• Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.

  2022cites this paper
• Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

  2021cites this paper
• The risks and trends of cardiac-specific mortality associated with chemotherapy or radiotherapy in a large cohort of non-elderly patients with non-small cell lung cancer

  2021cites this paper
• Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy

  2020cites this paper
• Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial.

  2020cites this paper
• Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung Cancer: A Systematic Review

  2017cites this paper
• Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

  2017influential citation
• Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.

  2017cites this paper
• COX-2 Inhibitors, a Potential Synergistic Effect with Antineoplastic Drugs in Lung Cancer

  2017cites this paper
• Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer

  2017cites this paper
• Locally Advanced Non-small Cell Lung Cancer and Targeted Therapy

  2017cites this paper
• Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.

  2016cites this paper
• A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer

  2016cites this paper
• [Radiotherapy and targeted therapy/immunotherapy].

  2016cites this paper
• AB062. COX-2 inhibitors, a potential synergistic effect with antineoplastic drugs in lung cancer.

  2016cites this paper
• The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer

  2016cites this paper
• 紫杉醇联合卡铂三周方案同步胸部放疗治疗不宜手术的局部晚期非小细胞肺癌疗效和安全性研究：一项来自单中心的回顾性研究

  2016cites this paper
• Combined Modality Therapy for Thoracic and head and Neck Cancers: A Review of Updated Literature Based on a Consensus Meeting

  2016cites this paper
• Advances in Radiotherapy for Locally Advanced NSCLC

  2015cites this paper
• Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.

  2015cites this paper
• Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

  2015cites this paper
• Afatinib with Concurrent Radiotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer

  2014cites this paper
• EGFR-TKI联合放疗治疗晚期非小细胞肺癌的研究进展

  2014cites this paper
• Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer

  2014cites this paper
• Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer.

  2014cites this paper
• Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC.

  2014cites this paper
• Gefitinib combined with γ-ray stereotactic body radiation therapy has better efficacy than gefitinib alone for senile lung adenocarcinoma patients with EGFR mutations as first-line regimen

  2014cites this paper
• Arrhythmias in Cancer and Cancer Treatment: A Review

  2014cites this paper
• Influence de l’inhibition des signaux de survie et radiosensibilisation des cancers pulmonaires

  2014cites this paper
• Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer

  2014cites this paper
• Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.

  2013influential citation
• EGFR inhibition in non-small cell lung cancer: current evidence and future directions

  2013cites this paper
• Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

  2013cites this paper
• Clinical study on gefitinib combined with γ-ray stereotactic body radiation therapy as the first-line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085)

  2013cites this paper
• Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

  2013cites this paper
• Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience.

  2013cites this paper
• Molecularly targeted therapies in locally advanced non-small-cell lung cancer.

  2013cites this paper
• The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC

  2013cites this paper
• New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.

  2013cites this paper
• Promising new molecule-targeted therapies and their integration into radiotherapy for lung cancer

  2013cites this paper
• Challenges in optimizing chemoradiation in locally advanced non small-cell lung cancers in India

  2013cites this paper
• Targeting VEGF in lung cancer

  2012cites this paper
• Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

  2012cites this paper
• Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.

  2012cites this paper
• Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.

  2012cites this paper
• Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.

  2012influential citation
• Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome?

  2012cites this paper
• [Targeted agents in the treatment of lung cancer].

  2012cites this paper
• Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.

  2012cites this paper
• The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.

  2012cites this paper
• Association des thérapeutiques ciblées anti-EGFR avec la radio-chimiothérapie chez les patients présentant un cancer bronchique non à petites cellules localement avancé

  2012cites this paper
• Summary of presentations from the 11th targeted therapies for lung cancer meeting: radiation oncology.

  2011cites this paper
• [Targeted therapies and radiation therapy in non-small cell lung cancer].

  2011cites this paper
• EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.

  2011cites this paper
• Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.

  2011cites this paper
• Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

  2011cites this paper
• Chemoradiation therapy in nonsmall cell lung cancer

  2011cites this paper
• Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?

  2011cites this paper
• Targeted Therapy in Lung Cancer: Lessons Learned from Past Experiences

  2011cites this paper
• Clinical study on gefitinib combined with γ-ray stereotactic radiotherapy for senile patients with adenocarcinoma of lung as the first-line regimen

  2011cites this paper
• Thérapies ciblées et radiothérapie dans les cancers bronchiques non à petites cellules

  2011cites this paper
• New molecular targeted therapies integrated with radiation therapy in lung cancer.

  2010cites this paper
• New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer

  2010cites this paper
• Non-Small Cell Lung Cancer in Stages I–IIIB

  2010cites this paper
• Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study

  2010cites this paper
• Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

  2010cites this paper
• A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer.

  2010cites this paper
• A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and Maintenance Gefitinib for Patients with Stage III Non-small Cell Lung Cancer

  2010cites this paper
• Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy.

  2010cites this paper
• A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer.

  2010cites this paper
• Recent Advances in Combined Modality Therapy

  2010cites this paper
• Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  2010cites this paper
• 35 – Tumors of the Lung, Pleura, and Mediastinum

  2010cites this paper
• Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives

  2009cites this paper
• État des lieux des associations chimioradiothérapeutiques et place potentielle des thérapies ciblées dans les cancers bronchiques non à petites cellules

  2009cites this paper
• Combination of radiotherapy and chemotherapy in locally advanced NSCLC

  2009cites this paper
• Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors

  2009cites this paper
• [State of the art in chemoradiotherapy combinations and potential role in targeting therapy approaches in nonsmall cell lung cancer].

  2009cites this paper
• Radiotherapy for locally advanced non-small cell lung cancer.

  2009cites this paper
• Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.

  2009cites this paper
• The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.

  2008cites this paper